Get the Stockscreener App
141.92
1.66%
2.32
After Hours:
141.92
Neurocrine Biosciences Inc stock is traded at $141.92, with a volume of 786.33K.
It is up +1.66% in the last 24 hours and up +10.09% over the past month.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See More
Previous Close:
$139.60
Open:
$139.08
24h Volume:
786.33K
Relative Volume:
0.89
Market Cap:
$14.08B
Revenue:
$2.41B
Net Income/Loss:
$305.80M
P/E Ratio:
48.11
EPS:
2.95
Net Cash Flow:
$492.20M
1W Performance:
+3.71%
1M Performance:
+10.09%
6M Performance:
+19.54%
1Y Performance:
+11.70%
1-Day Range:
$138.57
$142.91
1-Week Range:
$136.94
$142.91
52-Week Range:
$84.23
$154.61
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
141.92 | 13.85B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
152.88 | 69.31B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.16 | 47.34B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.76 | 43.88B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.75 | 21.08B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
404.81 | 13.78B | 2.99B | 1.21B | 1.13B | 25.06 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Is a relief rally coming for Neurocrine Biosciences Inc. holdersJuly 2025 Patterns & Technical Confirmation Trade Alerts - Newser
Is Neurocrine Biosciences Inc. showing signs of accumulation2025 Top Gainers & Fast Gaining Stock Reports - Newser
Is Neurocrine Biosciences Inc. being accumulated by smart moneyJuly 2025 Levels & Fast Entry and Exit Trade Plans - خودرو بانک
Technical Bounce Expected in Neurocrine Biosciences Inc. Next Week getLinesFromResByArray error: size == 0 - thegnnews.com
What to expect from Neurocrine Biosciences Inc. in the next 30 daysJuly 2025 Patterns & Weekly Top Gainers Trade List - Newser
Tick level data insight on Neurocrine Biosciences Inc. volatilityMarket Growth Review & Free Fast Gain Swing Trade Alerts - Newser
Neurocrine Biosciences, Inc. (NBIX) Beats Estimates on Neurology Drug Demand, Expands Payer Access - Yahoo Finance
Neurocrine Biosciences Inc. recovery potential after sell offLayoff News & Real-Time Volume Analysis Alerts - Newser
Can Neurocrine Biosciences Inc. hit a new high this monthTrade Ideas & AI Optimized Trading Strategy Guides - Newser
Does Neurocrine Biosciences Inc. fit your quant trading modelInsider Buying & Technical Confirmation Trade Alerts - Newser
Custom watchlist performance reports with Neurocrine Biosciences Inc.Market Growth Review & Free Fast Gain Swing Trade Alerts - Newser
Is Neurocrine Biosciences Inc. forming a reversal patternVolume Spike & Reliable Price Action Trade Plans - Newser
Risk vs reward if holding onto Neurocrine Biosciences Inc.July 2025 Catalysts & Reliable Entry Point Trade Alerts - Newser
Understanding Neurocrine Biosciences Inc.’s price movement2025 Technical Patterns & High Yield Stock Recommendations - Newser
Neurocrine Biosciences Inc. stock retracement – recovery analysisTrade Analysis Summary & Safe Capital Growth Tips - Newser
Will Neurocrine Biosciences Inc. stock go up soonMarket Performance Recap & AI Driven Stock Price Forecasts - Newser
Real time social sentiment graph for Neurocrine Biosciences Inc.Jobs Report & Weekly Breakout Opportunity Watchlist - Newser
Tools to monitor Neurocrine Biosciences Inc. recovery probabilityTrade Ideas & AI Enhanced Trading Signals - Newser
Historical volatility pattern of Neurocrine Biosciences Inc. visualizedMarket Performance Recap & Low Drawdown Investment Ideas - Newser
How Neurocrine Biosciences Inc. stock performs during market volatilityMarket Growth Summary & Weekly Setup with High ROI Potential - Newser
How to integrate Neurocrine Biosciences Inc. into portfolio analysis toolsEarnings Miss & Technical Entry and Exit Alerts - Newser
Ranking Neurocrine Biosciences Inc. among high performing stocks via tools2025 Macro Impact & Verified Momentum Stock Ideas - Newser
What Fibonacci levels say about Neurocrine Biosciences Inc. reboundProduct Launch & Verified High Yield Trade Plans - Newser
Will Neurocrine Biosciences Inc. price bounce be sustainableJuly 2025 Setups & Consistent Growth Equity Picks - Newser
Real time scanner hits for Neurocrine Biosciences Inc. explainedStop Loss & Weekly High Return Opportunities - Newser
Relative strength of Neurocrine Biosciences Inc. in sector analysisJuly 2025 Earnings & Real-Time Volume Analysis - Newser
Is it too late to sell Neurocrine Biosciences Inc.Quarterly Performance Summary & Expert-Curated Trade Recommendations - Newser
Neurocrine Biosciences Inc. stock trendline breakdownQuarterly Market Summary & Risk Managed Investment Strategies - Newser
Long term hold vs stop loss in Neurocrine Biosciences Inc.2025 Analyst Calls & AI Driven Price Predictions - Newser
Will Neurocrine Biosciences Inc. stock recover after recent dropWeekly Trend Summary & Long-Term Capital Growth Ideas - Newser
What’s next for Neurocrine Biosciences Inc. stock priceWeekly Profit Recap & Weekly Breakout Watchlists - Newser
Using portfolio simulators with Neurocrine Biosciences Inc. includedWeekly Market Outlook & Target Return Focused Stock Picks - Newser
Regression analysis insights on Neurocrine Biosciences Inc. performance2025 Top Gainers & Fast Gain Stock Tips - Newser
Can Neurocrine Biosciences Inc. recover in the next quarter2025 Pullback Review & Free Growth Oriented Trading Recommendations - Newser
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.09%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):